Facebook
Twitter
Telegram
Report an ErrorAmneal Pharmaceuticals Balance Sheet 2011-2024 | AMRX
Annual Balance Sheet Amneal Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
2.33 B | 2.6 B | 2.46 B | 2.47 B | 2.48 B | 2.44 B | 1.37 B | - | - | - | - | - | - |
Long Term Debt |
2.39 B | 2.59 B | 2.68 B | 2.77 B | 2.61 B | 2.63 B | 1.36 B | - | - | - | - | - | - |
Long Term Debt Current |
34.1 M | 30 M | 30.6 M | 44.2 M | 21.5 M | 21.4 M | - | - | - | - | - | - | - |
Total Non Current Liabilities |
2.56 B | 2.84 B | 2.88 B | 2.98 B | 2.77 B | 2.9 B | 1.42 B | - | - | - | - | - | - |
Total Current Liabilities |
847 M | 753 M | 677 M | 677 M | 550 M | 554 M | - | - | - | - | - | - | - |
Total Liabilities |
- | - | - | - | 3.32 B | 3.46 B | 1.72 B | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-490 M | -406 M | -276 M | -287 M | -378 M | -20.9 M | - | - | - | - | - | - | - |
Total Assets |
3.47 B | 3.8 B | 3.94 B | 4.01 B | 3.67 B | 4.35 B | 1.34 B | - | - | - | - | - | - |
Cash and Cash Equivalents |
91.5 M | 26 M | 248 M | 341 M | 151 M | 213 M | 74.2 M | 37.5 M | - | - | - | - | - |
Book Value |
3.47 B | 3.8 B | 3.94 B | 4.01 B | 347 M | 896 M | -376 M | - | - | - | - | - | - |
Total Shareholders Equity |
19.8 M | 298 M | 367 M | 345 M | 232 M | 505 M | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Amneal Pharmaceuticals
| 2024-Q1 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
2.38 B | 2.55 B | 2.56 B | 2.59 B | 2.61 B | 2.62 B | 2.67 B | 2.68 B | 2.69 B | 2.72 B | 2.73 B | 2.74 B | 2.74 B | 2.74 B | 2.74 B | 2.61 B | 2.61 B | 2.61 B | 2.61 B | 2.63 B | 2.63 B | 2.63 B | 2.63 B | 1.36 B | - | 1.36 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
2.64 B | 2.74 B | 2.76 B | 2.84 B | 2.84 B | 2.86 B | 2.86 B | 2.88 B | 2.91 B | 2.95 B | 2.94 B | 2.97 B | 2.97 B | 2.97 B | 2.97 B | 2.77 B | 2.77 B | 2.77 B | 2.77 B | 2.9 B | 2.9 B | 2.9 B | 2.9 B | 1.42 B | 1.42 B | 1.42 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-582 M | -401 M | -413 M | -406 M | -402 M | -399 M | -278 M | -276 M | -270 M | -266 M | -280 M | -287 M | -287 M | -287 M | -287 M | -378 M | -378 M | -378 M | -378 M | -20.9 M | -20.9 M | -20.9 M | -20.9 M | -383 M | -383 M | -383 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
3.46 B | 3.7 B | 3.63 B | 3.8 B | 3.87 B | 4.04 B | 3.89 B | 3.94 B | 3.97 B | 4.02 B | 3.96 B | 4.01 B | 4.01 B | 4.01 B | 4.01 B | 3.67 B | 3.67 B | 3.67 B | 3.67 B | 4.35 B | 4.35 B | 4.35 B | 4.35 B | 1.34 B | 1.34 B | 1.34 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
46.5 M | 109 M | 145 M | 26 M | 87.3 M | 92 M | 210 M | 248 M | 303 M | 278 M | 452 M | 347 M | 341 M | 341 M | 341 M | 151 M | 151 M | 151 M | 151 M | 213 M | 213 M | 213 M | 213 M | 74.2 M | 74.2 M | 74.2 M | - | 27.4 M | - | - | - | 65.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
- | - | - | 3.8 B | 3.87 B | 4.04 B | 3.89 B | 3.94 B | 3.97 B | 4.02 B | 3.96 B | 4.01 B | 4.01 B | 4.01 B | 4.01 B | 3.67 B | 3.67 B | 3.67 B | 3.67 B | 4.35 B | 4.35 B | 4.35 B | 4.35 B | 1.34 B | 1.34 B | 1.34 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
-63.7 M | 318 M | 135 M | 298 M | 297 M | 173 M | 407 M | 360 M | 383 M | 390 M | 367 M | 345 M | 303 M | 303 M | 303 M | 232 M | 232 M | 232 M | 232 M | 505 M | 505 M | 505 M | 505 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency